Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally adv... by Yoon-Koo Kang, Hyung-Don Kim, Min-Hee Ryu

Get full text

Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer by Yoon-Koo Kang, Jong Seok Lee, Hyung-Don Kim, Min-Hee Ryu, Young Soo Park, Hyungwoo Cho

Get full text

The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. by David L Chan, Katrin M Sjoquist, David Goldstein, Timothy J Price, Andrew J Martin, Yung-Jue Bang, Yoon-Koo Kang, Nick Pavlakis

Get full text

Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐cen... by Jwa Hoon Kim, Min‐Hee Ryu, Changhoon Yoo, Heejung Chae, Hana Na, Moyoul Beck, Beom Su Kim, Moon‐Won Yoo, Jeong Hwan Yook, Byung Sik Kim, Ki‐Hun Kim, Chan Wook Kim, Yoon‐Koo Kang

Get full text

Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial by Funda Meric-Bernstam, Sun Young Rha, Erika Hamilton, Yoon-Koo Kang, Diana L. Hanna, Syma Iqbal, Keun-Wook Lee, Jeeyun Lee, Muralidhar Beeram, Do-Youn Oh, Jorge Chaves, Rachel A. Goodwin, Jaffer A. Ajani, Lin Yang, Rajen Oza, Elena Elimova

Get full text

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors by Yun Zhang, Bhumsuk Keam, Jayesh Desai, Ben Markman, Shahneen Sandhu, Michael Millward, Yoon-Koo Kang, Chia-Chi Lin, Yee Chao, Sanjeev Deva, Jong Seok Lee, Chia-Jui Yen, Michael Jameson, Ming-Mo Hou, Chang-Hsien Lu, Kun-Ming Rau, Kyung-Hun Lee, Lisa Horvath, Michael Friedlander, Andrew Hill, Paula Barlow, Chi-Yuan Wu, Liang Liang, John Wu, Virginia Paton

Get full text